Filtered By:
Condition: Rheumatoid Arthritis
Management: Food and Drug Administration (FDA)
This page shows you your search results in order of date.
Order by Relevance | Date
Total 2 results found since Jan 2013.
Can ‘toxic’ bilirubin treat a variety of illnesses?
Generations of medical and biology students have been instilled with a dim view of bilirubin. Spawned when the body trashes old red blood cells, the molecule is harmful refuse and a sign of illness. High blood levels cause jaundice, which turns the eyes and skin yellow and can signal liver trouble. Newborns can’t process the compound, and although high levels normally subside, a persistent surplus can cause brain damage.
Yet later this year up to 40 healthy Australian volunteers may begin receiving infusions of the supposedly good-for-nothing molecule. They will be participating in a phase 1 safety trial, sponsored ...
Source: ScienceNOW - June 8, 2023 Category: Science Source Type: news
An Update on the Cardiovascular Risks Associated With NSAIDs
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used medications for osteoarthritis, rheumatoid arthritis, and myalgias (Table 1). In 2005, the United States Food and Drug Administration (FDA) placed a black box warning in the prescribing information of NSAIDs for the risk of myocardial infarction (MI) and stroke associated with their use.1 Last year, the FDA met to discuss new literature on NSAID cardiovascular (CV) risk to determine how it would affect prescription labeling.2 There were several observational studies and meta-analyses reviewed.
Source: The Journal for Nurse Practitioners - October 31, 2015 Category: Nursing Authors: Jason Babby, Archna Lall Tags: Prescription Pad Source Type: research
